Sight Sciences: Early Wins on Coverage and Data — A Tactical Swing Trade, Not a Buy-and-Hold

Hook / Thesis
Sight Sciences ($8.60) is showing real forward progress: commercial adoption signals (UnitedHealthcare coverage for the OMNI system) and two-year durability data for TearCare are removing key adoption barriers that have dogged the name. That progress is meaningful and could drive above-consensus revenue growth in the near term, but the company is still unprofitable, has negative free cash flow, and trades at rich multiples. For traders there is a defined setup to capture upside from improving adoption while limiting downside exposure.

This is a tactical, swing-oriented idea: enter on a mild pullback to $8.40, target $10.00 on successful near-term commercial momentum, and cut the trade at $7.30 if adoption or reimbursement signals disappoint. The plan leans on improving payer coverage, published 24-month clinical durability for TearCare, and an ongoing cost-utility argument vs prescription therapy — but it respects a valuation that already prices in a lot of success.

Business Overview - What Does Sight Sciences Do and Why Markets Should Care

Sight Sciences develops ophthalmic devices focused on two core areas: surgical glaucoma and dry eye disease. Its Surgical Glaucoma segment centers on the OMNI Surgical System for minimally invasive glaucoma surgery (MIGS). The Dry Eye segment sells the TearCare System and consumables for treating meibomian gland dysfunction and dry eye disease.

Why the market should care: these are sizable, multi-year markets with a strong clinical need. Payer reimbursement and durable clinical outcomes are the two necessary ingredients for durable commercial adoption. Sight Sciences has recently checked both boxes in part: UnitedHealthcare added OMNI to its covered procedures (09/09/2025), potentially extending access to roughly 30 million lives, and the company published 24-month SAHARA data (07/29/2025) showing durable TearCare benefits. A separate cost-utility analysis (07/30/2025) demonstrated ~$903 annual per-patient savings versus cyclosporine, a direct commercial message to payers and health systems.

Where the numbers sit today

Those numbers tell a compact story: the market is assigning premium multiples (P/S ~5.6x; P/B ~8.8x) despite negative earnings and negative free cash flow. There is cash on the balance sheet ($3.89 per share) but operating cash burn remains a near-term reality. Enterprise value metrics (EV/sales ~5.13x, EV/EBITDA negative) reinforce that the company is priced for growth that must materialize.

Technical and market structure notes
Short interest has risen and is meaningful: the most recent settlement shows ~1.25M shares short (settlement date 09/15/2026) and days-to-cover of ~8.5. Trading volume has been uneven; the 30-day average volume sits near ~310k shares, versus occasional spikes on news days. On the chart, short-term moving averages are around the current price (SMA10 ~$8.86, SMA20 ~$8.61, SMA50 ~$8.13) and RSI is neutral (~52.7), implying there is room for a measured move in either direction depending on flow.

Trade Plan (actionable)

• Direction: Long.
• Entry: Buy at $8.40.
• Stop loss: $7.30.
• Target: $10.00.
• Horizon: mid term (45 trading days) - aim to capture a near-term rerating or adoption update while limiting exposure to a lengthier execution cycle.

Rationale: an entry at $8.40 buys a modest pullback below current levels and closer to the SMA20, offering a reasonable risk-to-reward into a 17.9% upside to $10.00 and ~13% downside to the $7.30 stop. The mid-term (45 trading days) horizon is chosen to give the market time to digest incremental commercial metrics (payer rollouts, purchase orders, quarterly revenue cadence) without committing to a multi-quarter revenue execution assumption.

Catalysts to watch (near-term)

• Additional payer coverage announcements or expanded indications for OMNI - each incremental payer win meaningfully increases addressable access.
• Quarterly commercial metrics showing sequential unit growth for OMNI or TearCare (procedure counts, consumable attach rates).
• Publication or real-world data releases reinforcing TearCare durability and cost-savings versus prescription therapy.
• Evidence of improving gross margins or a concrete path to reduced operating cash burn.

Risks (balanced, and why they matter)

• Execution risk: Adoption of surgical devices and procedure-driven revenue takes time. If procedure volumes or consumable attach rates don’t pick up, revenue growth can disappoint quickly.
• Reimbursement concentration: While UnitedHealthcare coverage is an important win, broader reimbursement across other large payers and Medicare policy alignment are required for sustained volume growth.
• Profitability and cash burn: Free cash flow was negative (about -$23.3M) and the company remains unprofitable (EPS -$0.54). Continued cash burn could pressure the stock absent clear revenue inflection.
• Competitive pressure: The dry eye and MIGS spaces have established competitors and new entrants; market share gains are never guaranteed.
• Short-seller pressure and volatility: Elevated short interest creates the potential for outsized swings on headline news in either direction.

Counterargument: One could reasonably argue the stock already prices in the positive outcomes the company has published. Premium multiples and a market cap approaching $475M imply high future penetration of both OMNI and TearCare. If adoption stalls, misses guidance, or the company needs to raise capital, downside could be steep. In that scenario, this trade would be a loser even if the clinical data remains intact.

How I would be proven wrong
My base trade thesis would break down if we see any of the following within the 45-trading-day horizon: no sequential improvement in procedure counts or consumable sales, loss of a material payer coverage decision, a meaningful miss on quarterly sales guidance, or accelerated cash burn requiring capital raises. Those outcomes would argue for closing the long and potentially moving to a neutral or short stance.

What would make me more bullish
Sustained evidence of improved unit economics (higher consumable attach per procedure), broader payer coverage beyond UnitedHealthcare, and a demonstrable path to positive operating leverage would push me from a tactical swing trade to a longer-term position. Similarly, margin expansion and a pivot toward positive free cash flow would materially change the risk-reward profile.

Bottom line
Sight Sciences has cleared important commercial and clinical hurdles that validate parts of its narrative. That progress supports a tactical, medium-horizon long trade into improving adoption metrics. However, the company’s current valuation and negative cash flow argue for strict risk management. Enter at $8.40, stop at $7.30, and take profit at $10.00 within roughly 45 trading days unless company fundamentals or the macro picture materially change.

Key points

• UnitedHealthcare coverage (09/09/2025) and 24-month SAHARA data (07/29/2025) are tangible commercial and clinical positives.
• Valuation is demanding: market cap ~$474M, P/S ~5.6x, negative EPS and free cash flow.
• Entry at $8.40 gives defined downside to $7.30 and a clear target at $10.00 for a mid-term swing.
• Watch payer rollouts, consumable attach rates, and quarterly revenue prints as the primary catalysts.